AXQ Capital LP Makes New Investment in Doximity, Inc. (NASDAQ:DOCS)

AXQ Capital LP acquired a new position in Doximity, Inc. (NASDAQ:DOCS) during the fourth quarter, HoldingsChannel reports. The institutional investor acquired 16,162 shares of the company’s stock, valued at approximately $863,000.

A number of other large investors have also added to or reduced their stakes in the company. FMR LLC increased its position in shares of Doximity by 30.5% during the 3rd quarter. FMR LLC now owns 6,837,733 shares of the company’s stock valued at $297,920,000 after purchasing an additional 1,598,602 shares during the last quarter. State Street Corp increased its position in shares of Doximity by 2.5% during the 3rd quarter. State Street Corp now owns 3,693,982 shares of the company’s stock valued at $160,947,000 after purchasing an additional 88,922 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Doximity by 19.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,856,984 shares of the company’s stock valued at $124,503,000 after purchasing an additional 472,565 shares during the last quarter. Los Angeles Capital Management LLC boosted its holdings in Doximity by 33.7% during the 4th quarter. Los Angeles Capital Management LLC now owns 870,322 shares of the company’s stock valued at $46,466,000 after acquiring an additional 219,448 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Doximity by 3.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 778,524 shares of the company’s stock valued at $41,565,000 after acquiring an additional 25,523 shares during the period. Institutional investors own 87.19% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Bank of America boosted their price objective on Doximity from $54.00 to $57.00 and gave the company a “neutral” rating in a report on Monday, January 6th. The Goldman Sachs Group boosted their price objective on Doximity from $58.00 to $80.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Canaccord Genuity Group upped their target price on Doximity from $60.00 to $71.00 and gave the stock a “hold” rating in a report on Friday, February 7th. Mizuho upped their target price on Doximity from $55.00 to $65.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. Finally, Piper Sandler upgraded Doximity from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $31.00 to $78.00 in a research note on Friday, February 7th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $64.22.

Insider Transactions at Doximity

In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the transaction, the director now owns 6,360 shares in the company, valued at approximately $366,463.20. This represents a 75.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 37.40% of the company’s stock.

Doximity Stock Up 0.4 %

Shares of DOCS opened at $63.01 on Friday. Doximity, Inc. has a 52 week low of $22.96 and a 52 week high of $85.21. The company has a market capitalization of $11.76 billion, a price-to-earnings ratio of 63.01, a PEG ratio of 4.10 and a beta of 1.34. The stock’s 50-day moving average price is $64.42 and its 200-day moving average price is $53.39.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.